Company intelligence / Profile preview

Huaren Biotechnology

Qingdao, Shandong, Chinaen.hbhrsw.cn ↗

Ownership: Private
Development stage: Other

Overview

Founded in 2012, Huaren Biotechnology has evolved through several corporate restructurings and relocations. It focuses primarily on developing innovative protein-based therapeutics for diseases with significant unmet need. The company has advanced at least one program into pre-IND collaboration with academic partners and has been recognized as a National High-Tech Enterprise since 2018. As of April 2024, it operates under the name B&K Corporation Limited after conversion to a joint stock company headquartered in Qingdao, China

Modalities: Protein drugsbiologics and related modalities
Industry: Biotech

Partnerships

Collaborated with Institute of Bioengineering of AMMS for early-stage R&D ("Pro‑101‑2") starting August 2013

Beyond the preview

Go deeper on Huaren Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huaren Biotechnology.

Explore the full profile